324 filings
Page 3 of 17
8-K
wiiuzhcyh dp4a02m9
17 Feb 22
PolarityTE Announces Allowance of Fourth U.S. Patent
8:00am
8-K
3cpb4gtb9c55wdca6
11 Feb 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
g6wsg9kjywa
18 Jan 22
PolarityTE Announces U.S. FDA Approval of IND for Pivotal Phase 3 Study of SkinTE® to
8:00am
8-K
bp8k367
23 Dec 21
Departure of Directors or Certain Officers
4:30pm
8-K
m6u8don3s3
20 Dec 21
PolarityTE Announces Submission of Complete Response to FDA’s Clinical Hold Correspondence for SkinTE® Investigational New Drug Application
8:00am
8-K
kt3ja
17 Dec 21
Entry into a Material Definitive Agreement
5:00pm
8-K
5zeuwb7sif1te
10 Nov 21
PolarityTE Reports Third Quarter Financial Results and Provides Business Update
7:00am
8-K
keflm 7p7rdords1t98
7 Oct 21
PolarityTE Provides Update on Investigational New Drug Application
8:00am
8-K
n0z2uz3vtpp6wzhx4bbr
1 Oct 21
Amendments to Articles of Incorporation or Bylaws
4:46pm
8-K
szo ke0qh
9 Sep 21
Regulation FD Disclosure
8:01am
8-K
jvcpm k1e
2 Sep 21
PolarityTE Appoints Richard Hague as Chief Executive Officer and Elects David Seaburg
8:00am
8-K
htw5p 3vn8be
27 Aug 21
Departure of Directors or Certain Officers
12:00am
8-K
2pa7 hvefh
24 Aug 21
Departure of Directors or Certain Officers
8:00am
8-K
e2ni9ozkwrp oh6m
16 Aug 21
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:31pm
8-K
s2zvbt8t
12 Aug 21
PolarityTE Reports Second Quarter Financial Results and Provides Business Update
4:00pm
8-K
4kgyxqeo1 qhnv60gd
28 Jul 21
Regulation FD Disclosure
8:00am
8-K
ih0zcux
26 Jul 21
Other Events
8:00am
8-K
r1m9t1 w39i3
12 Jul 21
PolarityTE Receives Notice of Allowance for Chinese Patent
8:00am
8-K
d7hd4qejqoepr oj
17 Jun 21
Termination of a Material Definitive Agreement
4:45pm
8-K
t8pmsuszueec e6r
13 May 21
PolarityTE Reports First Quarter Results and Provides Business Update
4:26pm